Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | SHFS 0.1324 -61.39% | XXII 0.1977 -8.34% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | RBNE 0.19 -2.56% | YFOR 0.2236 -1.58% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | TQQQ 66.29 -0.20% | TSLL 9.76 -1.21% | VZ 44.66 -1.19% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | GRAB 2.79 -2.11% | AIOK 12.02 182.82% | SQQQ 39.68 0.20% | ONDS 6.2 2.99% | LABT 0.31 -36.67% | AAPL 347.725 -0.14% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | IREN 24.905 -2.37% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | NFLX 65.85 -1.79% | QID 14.55 0.14% | CLRO 3.25 69.27% | WULF 11.32 0.00%
NENeuphoria Therapeutics Inc. logo

Neuphoria Therapeutics Inc. (NEUP)

NASDAQ Global Market · Currency in USD
$3.44 ▼ -0.04 (-1.15%)
At close: Oct 23, 4:00 PM ET. Market closed.
$3.44 ▲ +0.00 (+0.00%)
After hours: Oct 23, 7:30 PM ET

Summary

Previous Close
$3.48
Open
$3.47
Day's Range
$3.41 – $3.59
52 Week Range
$3.19 – $6.01
Volume
72,769
Avg. Volume
138,038
Market Cap
$18.61M
Beta (5Y Monthly)
0.75
PE Ratio (TTM)
--
EPS (TTM)
-$3.42
Earnings Date
--
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$7.00

Profile: Neuphoria Therapeutics Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
1
CEO
Spyridon Papapetropoulos

Neuphoria Therapeutics Inc., a clinical stage biopharmaceutical company, develops novel allosteric ion channel modulators for patients with serious central nervous system disorders in Australia. Its lead product candidate is BNC210, an oral, proprietary, selective negative allosteric modulator of the alpha7 nicotinic acetylcholine receptor for post-traumatic stress disorder. The company also develops Merck alpha7 positive allosteric modulators.

Earnings

DateEst.Actual
Sep 18, 2026-$0.56-$0.56Beat
Sep 2, 2026-$0.56-$0.56Beat
May 15, 2026-$0.56-$0.09Beat
Feb 17, 2026-$0.56-$0.77Miss
Nov 14, 2025-$1.33-$4.41Miss
Sep 29, 2025-$0.56-$5.79Miss

Analyst view

Consensus price target
$7.00 ▲ +103.5%
Range $7.00 – $7.00
Rating: Buy
Buy 50% · Hold 50% · Sell 0%

Get free alerts on NEUP and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.